Visa Drugs & Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 4.00 Cr
- Paid Up Capital ₹ 4.00 Cr
- Company Age 16 Year, 7 Months
- Last Filing with ROC 31 Mar 2016
- Satisfied Charges ₹ 359.90 Cr
- Revenue Growth 31.98%
- Profit Growth 54.40%
- Ebitda 42.47%
- Net Worth 17.96%
- Total Assets 25.59%
About Visa Drugs & Pharmaceuticals
Company Details
-
Location
Kolkata, West Bengal, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U85100WB2008PTC127222
-
Company No.
127222
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
07 Jul 2008
-
Date of AGM
30 Sep 2016
-
Date of Balance Sheet
31 Mar 2016
-
Listing Status
Unlisted
-
ROC Code
Roc Kolkata
Industry
Who are the key members and board of directors at Visa Drugs & Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ramdeo Ram
|
Director | 01-Apr-2016 | Current |
|
Phool Yadav
|
Director | 27-Jan-2017 | Current |
Financial Performance of Visa Drugs & Pharmaceuticals.
Visa Drugs & Pharmaceuticals Private Limited, for the financial year ended 2016, experienced significant growth in revenue, with a 31.98% increase. The company also saw a substantial improvement in profitability, with a 54.4% increase in profit. The company's net worth Soared by an impressive increase of 17.96%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Visa Drugs & Pharmaceuticals?
In 2016, Visa Drugs & Pharmaceuticals had a promoter holding of 43.45% and a public holding of 56.55%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Venus Pharmagenerics Private LimitedRamdeo Ram and Phool Yadav are mutual person
-
Concept Cartonz Private Limited
Ramdeo Ram and Phool Yadav are mutual person
-
Aleris Reality Private Limited
Ramdeo Ram is a mutual person
Charges (Loans)
₹0
₹359.90 Cr
Charges Breakdown by Lending Institutions
- Syndicate Bank : 200.65 Cr
- Allahabad Bank : 90.00 Cr
- State Bank Of India : 69.25 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 12 Aug 2016 | Syndicate Bank | ₹97.00 Cr | Satisfied |
| 27 Nov 2014 | Syndicate Bank | ₹103.65 Cr | Satisfied |
| 20 Aug 2011 | State Bank Of India | ₹69.25 Cr | Satisfied |
| 04 Jun 2010 | Allahabad Bank | ₹35.00 Cr | Satisfied |
| 10 Apr 2010 | Allahabad Bank | ₹27.50 Cr | Satisfied |
How Many Employees Work at Visa Drugs & Pharmaceuticals?
Visa Drugs & Pharmaceuticals has a workforce of 46 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Visa Drugs & Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Visa Drugs & Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
